Hydroxyprocaine was invented as a local anesthetic drug that possessed the antibacterial properties. Information about the current use of this drug is not available.

Nicafenine, a quinoline derivative, is an analgesic.

Sifaprazine [FI 4303] is a substituted arylpiperazine with a similar structure to mianserin. Sifaprazine was undergoing preclinical evaluation with Ferrer in Spain as a potential antidepressant. However, no recent development has been reported.

Nexopamil [LU 49938] is the (S)-enantiomer of a phenylalkylamine derivative and has calcium channel blocking and serotonin2 receptor antagonist activity. Nexopamil's significant antifibrillatory effect during both coronary artery occlusion and abrupt reperfusion is reliably tracked by T-wave alternans magnitude. Because the major component of the protection could be reproduced by blockade of the L-type calcium channel with diltiazem, nexopamil's antiarrhythmic action appears to be due mainly to blockade of this channel. Nexopamil's antiplatelet action through blockade of 5-HT2 receptors may confer additional protection against reperfusion arrhythmias. Nexopamil was discontinued in phase 2 for angina pectoris in European Union.

Osemozotan (also known as MKC-242) was developed as a selective 5-HT1A receptor agonist. Experiments on animal have shown that osemozotan improved most abnormal behaviors such as isolation rearing. Osemozotan was being investigated for the treatment of pain, aggressive behavior, anxiety, depression, obsessive-compulsive disorder, and drug dependence with methamphetamine and cocaine. However, all these studies were suspended. In the USA osemozotan participated in phase II clinical trial for the insomnia patients, however, the study was terminated because of the license agreement.

Delfantrine is an analgesic, antiinflammatory agent, developed by Ciba.

Darbufelone mesylate is a dual inhibitor of cellular prostaglandin and leukotriene production. Darbufelone potently inhibits PGHS-2 (IC50 = 0.19 uM) but is much less potent with PGHS-1 (IC50= 20 uM). Darbufelone is a dual inhibitor of cellular PGF2R and LTB4 production. Darbufelone is orally active and nonulcerogenic in animal models of inflammation and arthritis. Darbufelone mesylate was in phase III clinical trials by Pfizer and Zhuhai United Laboratories for the treatment of rheumatoid arthritis.

Alpiropride (RIV-2093) is a dopamine D2-receptor antagonist structurally similar to sulpiride. Alpiropride has been given orally for the treatment and prophylaxis of migraine.

Information in the scientific papers related to the biological and/or pharmacological application of amindocate is absent.

Tifurac is a benzofuranacetic acid derivative patented by Syntex, Inc. as an analgesic, anti-inflammatory, and antipyretic agent. In preclinical models, Tifurac can exert anti-inflammatory and analgesic activity in rat paw edema assay and mouse writhing assay.